PMID- 36199793
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221007
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy 
      Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A 
      Retrospective Real-World Study.
PG  - 3645489
LID - 10.1155/2022/3645489 [doi]
LID - 3645489
AB  - BACKGROUND: Most patients with small-cell lung cancer (SCLC) have extensive-stage 
      (ES) disease with a poor prognosis. Immunotherapy has shown good therapeutic 
      effects in the treatment of ES-SCLC. We performed a real-world retrospective 
      study to evaluate the safety and efficacy of PD-L1 inhibitors plus chemotherapy 
      in patients with ES-SCLC. METHOD: A total of 224 patients diagnosed with ES-SCLC 
      between March 2017 and April 2021 were included, of which 115 received only 
      etoposide-platinum (EP) chemotherapy,and 109 received programmed cell-death 
      ligand 1 (PD-L1) inhibitors and EP. RESULTS: Immune checkpoint inhibitors (ICIs) 
      plus platinum were associated with a significant improvement in overall survival 
      (OS), with a hazard ratio (HR) of 0.60 (95% CI, 0.42-0.85; P=0.0054); median OS 
      was 19 months in the ICIs plus EP group vs. 12 months in the EP group. The median 
      progression-free survival (PFS) was 8.5 and 5.0 months, respectively (HR for 
      disease progression or death, 0.42; 95% CI, 0.31-0.57; P < 0.0001). Male patients 
      <65 years old, Stage IV, PS 0-1, without liver and brain metastasis had a better 
      OS in the ICIs plus EP group than the EP group. The PFS and OS in the durvalumab 
      plus chemotherapy group were insignificantly longer than that of the atezolizumab 
      plus chemotherapy group. Any adverse effects (AEs) of grade 3 or 4 occurred in 50 
      patients (45.9%) in the ICIs plus EP group and 48 patients (41.7%) in the EP 
      alone group. The most common immune-related AEs (irAEs) were immune 
      hypothyroidism events (17.1%, 7/41), immune dermatitis (9.8%, 4/41), and immune 
      pneumonia (9.8%, 4/41) in the durvalumab plus platinum-etoposide group. Immune 
      liver insufficiency (10.3%, 7/68) and immune hypothyroidism (8.8%, 6/68) were the 
      most common irAEs in the atezolizumab plus platinum-etoposide group. CONCLUSION: 
      This study shows that adding PD-L1 inhibitors to chemotherapy can significantly 
      improve PFS and OS in patients with ES-SCLC and demonstrates its safety without 
      additional AEs.
CI  - Copyright (c) 2022 Jingjing Qu et al.
FAU - Qu, Jingjing
AU  - Qu J
AUID- ORCID: 0000-0002-8079-4722
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
AD  - The Clinical Research Center for Respiratory Diseases of Zhejiang Province, 
      Hangzhou, Zhejiang 310003, China.
FAU - Kalyani, Farhin Shaheed
AU  - Kalyani FS
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
FAU - Shen, Qian
AU  - Shen Q
AUID- ORCID: 0000-0001-5820-6034
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
AD  - The Clinical Research Center for Respiratory Diseases of Zhejiang Province, 
      Hangzhou, Zhejiang 310003, China.
FAU - Yang, Guangdie
AU  - Yang G
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
AD  - The Clinical Research Center for Respiratory Diseases of Zhejiang Province, 
      Hangzhou, Zhejiang 310003, China.
FAU - Cheng, Tianli
AU  - Cheng T
AD  - Thoracic Medicine Department 1, Hunan Cancer Hospital, Affiliated Tumor Hospital 
      of Xiangya Medical School of Central South University, Changsha, Hunan 410008, 
      China.
FAU - Liu, Li
AU  - Liu L
AUID- ORCID: 0000-0002-0377-3469
AD  - Lung Cancer and Gastroenterology Department, Hunan Cancer Hospital, Affiliated 
      Tumor Hospital of Xiangya Medical School of Central South University, Changsha, 
      Hunan 410008, China.
FAU - Zhou, Jianya
AU  - Zhou J
AUID- ORCID: 0000-0001-8196-0166
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
AD  - The Clinical Research Center for Respiratory Diseases of Zhejiang Province, 
      Hangzhou, Zhejiang 310003, China.
FAU - Zhou, Jianying
AU  - Zhou J
AUID- ORCID: 0000-0002-8924-935X
AD  - Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, 
      China.
AD  - The Clinical Research Center for Respiratory Diseases of Zhejiang Province, 
      Hangzhou, Zhejiang 310003, China.
LA  - eng
PT  - Journal Article
DEP - 20220926
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC9529407
COIS- The authors declare there are no conflicts of interest.
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/09/26
CRDT- 2022/10/06 02:13
PHST- 2022/02/11 00:00 [received]
PHST- 2022/06/15 00:00 [revised]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/10/06 02:13 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/09/26 00:00 [pmc-release]
AID - 10.1155/2022/3645489 [doi]
PST - epublish
SO  - J Oncol. 2022 Sep 26;2022:3645489. doi: 10.1155/2022/3645489. eCollection 2022.